• 1. Distribution and ecological risk assessment of typical antibiotics in the surface waters of seven major rivers, China?
  Environ. Sci.: Processes Impacts, 2021,23, 1088-1100
• 2. Enantiomeric helical TiO2 nanofibers modulate different peptide assemblies and subsequent cellular behaviors?
  Xu Jie,Deng Xu,Weili Wei RSC Adv., 2019,9, 29149-29153
• 3. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives 2-halopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Halopyridines 2-halopyridines

Introduction to (2-Bromopyridin-4-yl)(phenyl)methanamine and Its Significance in Modern Chemical Research

(2-Bromopyridin-4-yl)(phenyl)methanamine, with the CAS number 1624262-06-1, is a compound of significant interest in the field of pharmaceutical and chemical research. This molecule, featuring a brominated pyridine core linked to a phenyl group via a methanamine moiety, has garnered attention due to its versatile structural properties and potential applications in drug development.

The< strong> bromopyridine moiety is a key structural feature that contributes to the compound's reactivity and interaction with biological targets. Pyridine derivatives are widely recognized for their role in medicinal chemistry, often serving as pharmacophores in various therapeutic agents. The presence of a< strong> bromine atom at the 2-position of the pyridine ring enhances its electrophilicity, making it a valuable intermediate in synthetic chemistry. This property allows for further functionalization, enabling the creation of more complex molecules with tailored biological activities.

The< strong> phenyl group attached through the methanamine linkage provides additional stability and influences the electronic properties of the molecule. Phenyl rings are commonly found in biologically active compounds due to their ability to participate in hydrophobic interactions and π-stacking, which are crucial for binding to biological targets. The combination of these two aromatic systems in< strong> (2-Bromopyridin-4-yl)(phenyl)methanamine creates a scaffold that is both structurally diverse and functionally rich.

In recent years, there has been growing interest in developing small-molecule inhibitors targeting various kinases and other enzymes involved in cancer metabolism. The< strong> bromopyridin-4-yl moiety, in particular, has been explored as a key component in kinase inhibitors due to its ability to mimic ATP binding pockets. Studies have shown that pyridine-based inhibitors can effectively disrupt signaling pathways by inhibiting key enzymes such as tyrosine kinases, which are overexpressed in many cancers.

One notable area of research involving< strong> (2-Bromopyridin-4-yl)(phenyl)methanamine is its potential application as an intermediate in the synthesis of antiviral agents. The bromine atom at the 2-position of the pyridine ring allows for cross-coupling reactions with various nucleophiles, enabling the introduction of diverse functional groups. These reactions are pivotal in constructing complex molecular architectures that can interact with viral proteases and other essential viral enzymes.

The compound's< strong> phenyl-methanamine structure also suggests its utility in developing neurokinin receptor antagonists. Neurokinin receptors are involved in various physiological processes, including pain perception and inflammation. Inhibitors targeting these receptors have shown promise in treating conditions such as migraine and chronic pain syndromes. The< strong> bromopyridin-4-yl moiety's ability to modulate receptor activity makes it an attractive scaffold for further derivatization.

The synthesis of< strong> (2-Bromopyridin-4-yl)(phenyl)methanamine involves multi-step organic transformations that highlight its synthetic versatility. The bromination of pyridine derivatives is a well-established method for introducing electrophilic centers, while cross-coupling reactions such as Suzuki or Buchwald-Hartwig couplings allow for the introduction of phenyl groups. These synthetic strategies are not only efficient but also scalable, making< strong> (2-Bromopyridin-4-yl)(phenyl)methanamine accessible for further research and development.

In conclusion, the compound< strong> (2-Bromopyridin-4-yl)(phenyl)methanamine, CAS number 1624262-06-1, represents a promising candidate for drug discovery and chemical research. Its unique structural features, including the< strong> bromopyridine,< strong> phenyl, and methanamine moieties, provide a rich platform for exploring new therapeutic agents. As research continues to uncover new applications and synthetic methodologies, this compound is poised to play a significant role in advancing pharmaceutical science.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)